Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arcion Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Arcion Therapeutics is focusing its development efforts on an existing chemical entity, clonidine, but its theory is more novel: that much or all of the abnormal pain signaling associated with neuropathic pain occurs in the skin. Thus it is trying to develop a topical form of clonidine, an alpha-2 adrenergic receptor agonist already marketed for high blood pressure. Arcion has uncovered a variety of mechanisms by which clonidine may relieve pain and hopes to soon begin a Phase IIb trial in diabetic neuropathy. The goal: a product that is easy to use and avoids many of the side effects associated with current treatments.
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091673

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel